The US government announced several significant changes to hospital antibiotic reimbursement by Medicare & Medicaid (CMS) in US hospitals.
Antabio Receives QIDP Designation from the U.S. FDA for the Development of Its Metallo Beta-Lactamase inhibitor ANT2681
The QIDP status provides ANT2681 with a five-year extension of data exclusivity as well as eligibility for Fast Track designation and priority review of its New Drug Application (NDA) for cUTI once submitted.
Antabio’s Novel Metallo β-Lactamase Inhibitor to be presented at the ASM Microbe Conference, June 20-24, San Francisco
Two presentations will focus on Antabio’s ANT2681, a novel Metallo β-Lactamase Inhibitor that restores the efficacy of Meropenem against clinical strains of NDM-producing CRE.
We are pleased to announce that Antabio’s CEO Marc Lemonnier has been appointed as a new member of the Scientific Advisory Board (SAB) of JPIAMR.
New investors Omnes, BNP Paribas Développement and Sham Innovation Santé invest an additional €5.2M on top of the €7.3M first closing announced in October 2017.
Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, is pleased to announce the addition of four highly successful and accomplished biotech executives to the management team. These appointments come soon after the first closing of Antabio’s Series A financing round and notification that Antabio has been selected as one of 18 out of 368 international candidates for a CARB-X subsidy award of up to $8,9 million.
ANTABIO raises € 7.3M Series A Financing to Develop Novel Treatments against Drug-Resistant Gram-negative infections
Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today the completion of a €7.3M series A financing with subscriptions from investment funds iXO Private Equity, IRDI SORIDEC Gestion, Galia Gestion and from the company’s historical investors including former President of OM Pharma Christophe Ricard.
ANTABIO awarded up to $8.9M from CARB-X to accelerate the development of its new treatment for chronic infections in Cystic Fibrosis patients
Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today that it has been awarded up to $8.9 million non-dilutive funding from CARB-X, the world’s largest public-private partnership devoted to antibacterial R&D. Antabio was selected by CARB-X from a group of 368 applicants worldwide and is part of the first cohort that includes companies from Continental Europe.
Antabio’s CEO Marc Lemonnier has been elected at the Board of Directors of the BEAM Alliance (Biopharmaceutical companies from Europe innovating in Anti-Microbial resistance research) further to the alliance’s Extraordinary General Assembly held in Paris on 20 December 2016. The BEAM Alliance represents European biopharmaceutical companies involved in developing innovative products to tackle antimicrobial resistance.